This study focuses on people with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal protein deposits build up in the heart muscle, leading to heart failure. The main treatment being studied is coramitug (also known as NNC6019-0001), which is given through an intravenous infusion. This medication is designed to target and remove the harmful protein deposits in the heart.

The purpose of this research is to evaluate how safe and effective long-term treatment with coramitug is for patients with ATTR-CM. During the study, participants will also receive standard medications for heart problems. The study will use various supportive medications including gadoteric acid as a contrast agent for imaging, paracetamol with codeine for pain relief, cetirizine for allergic reactions, and electrolyte solutions containing sodium chloride and other salts.

The study will last for 156 weeks (about 3 years). Throughout this time, participants will have regular check-ups to monitor their heart function and overall health. These check-ups will include various tests to measure heart performance and assess how well the treatment is working. The study will track any side effects that occur during the treatment period.